Combinations of phosphoinositide 3-kinase inhibitor...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/519 (2006.01) A61P 35/00 (2006.01)

Patent

CA 2753285

Combinations of PDK inhibitor compounds having Formula (I) and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hematopoietic malignancies. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

L'invention porte sur des combinaisons de composés inhibiteurs de PDK ayant la formule (I) et des agents chimiothérapeutiques, comprenant des stéréo-isomères, des isomères géométriques, des tautomères, des métabolites et des sels pharmaceutiquement acceptables de ceux-ci, qui sont utiles pour traiter des tumeurs malignes hématopoïétiques. L'invention porte sur des procédés d'utilisation de telles combinaisons pour un diagnostic, une prévention ou un traitement in vitro, in situ, et in vivo de tels troubles dans des cellules de mammifère, ou d'états pathologiques associés.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Combinations of phosphoinositide 3-kinase inhibitor... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combinations of phosphoinositide 3-kinase inhibitor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combinations of phosphoinositide 3-kinase inhibitor... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-2034571

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.